NCT05665075View on ClinicalTrials.gov

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 24, 2022

Primary Completion Date

December 24, 2023

Study Completion Date

December 24, 2025

Conditions
AML, Adult
Interventions
DRUG

QN-023a

NK cell therapy

DRUG

Cyclophosphamid

Lympho-conditioning Agent

DRUG

Fludarabine

Lympho-conditioning Agent

DRUG

Cytarabine

Lympho-conditioning Agent

DRUG

VP-16

Lympho-conditioning Agent

Trial Locations (1)

310003

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors
collaborator

Hangzhou Qihan Biotech Co.,Ltd.

INDUSTRY

lead

Zhejiang University

OTHER